Heron Therapeutics Inc. (HRTX)
NASDAQ: HRTX
· Real-Time Price · USD
1.30
-0.05 (-3.70%)
At close: Oct 16, 2025, 3:59 PM
1.34
2.97%
After-hours: Oct 16, 2025, 07:36 PM EDT
-3.70% (1D)
Bid | 1.13 |
Market Cap | 199.33M |
Revenue (ttm) | 149.69M |
Net Income (ttm) | -931K |
EPS (ttm) | -0.01 |
PE Ratio (ttm) | -130 |
Forward PE | 22 |
Analyst | Buy |
Dividends | n/a |
Ask | 1.51 |
Volume | 959,044 |
Avg. Volume (20D) | 1,718,365 |
Open | 1.34 |
Previous Close | 1.35 |
Day's Range | 1.30 - 1.38 |
52-Week Range | 1.04 - 2.68 |
Beta | 1.25 |
Ex-Dividend Date | n/a |
About HRTX
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol HRTX
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for HRTX stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsHeron Therapeutics Inc. is scheduled to release its earnings on
Nov 11, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
2 months ago
-28.26%
Heron Therapeutics shares are trading lower after ...
Unlock content with
Pro Subscription
5 months ago
+13.62%
Heron Therapeutics shares are trading higher after the company reported better-than-expected Q1 financial results.

2 months ago · seekingalpha.com
Heron Therapeutics, Inc. (HRTX) Q2 2025 Earnings Call TranscriptHeron Therapeutics, Inc. (NASDAQ:HRTX ) Q2 2025 Earnings Conference Call August 8, 2025 8:30 AM ET Company Participants Craig Alexander Collard - CEO & Director Ira Duarte - Executive VP & CFO Mark E....

2 months ago · fool.com
Heron (HRTX) Q2 Acute Care Jumps 56%Heron (HRTX) Q2 Acute Care Jumps 56%